RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
   Pharmacotherapy
   Radiotherapy
   Vaccination
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Pharmacotherapy Channel

subscribe to Pharmacotherapy newsletter
Latest Research : Cancer : Therapy : Pharmacotherapy

   EMAIL   |   PRINT
CDK2/FOXO1 as drug target to Prevent Tumors

Oct 13, 2006 - 1:11:00 AM , Reviewed by: Priya Saxena
"Quality control within dividing cells is essential because mistakes during duplication of the genetic code can lead to cancer. CDK2 is a key protein component in the cellular mechanism that leads to repair of damaged DNA."

 
[RxPG] Mayo Clinic researchers have found that a protein that initiates a "quality control check" during cell division also directs cell death for those cells damaged during duplication. This knowledge represents a potential "bulls eye" for targeting anti-tumor drugs. The findings appear in the current issue of Science.

The researchers examined a protein called cyclin-dependent kinase 2 (CDK2), which works as a "quality control inspector." As normal cells divide, they pause in the replication process when they find inaccurate genetic code embedded in their DNA. The health and well-being of offspring cells depends on accurate genetic code transfer from one generation of cells to the next. The Mayo researchers showed that when errors in genes are irreparable, CDK2 modifies another cellular protein -- FOXO1 -- to send a signal that results in the death of the cell. This protein-to-protein relationship invites targeted drug intervention to control unregulated growth of cancer cells.

"Quality control within dividing cells is essential because mistakes during duplication of the genetic code can lead to cancer," says Donald Tindall, Ph.D., co-leader of the Mayo Clinic Cancer Center prostate cancer research program. "CDK2 is a key protein component in the cellular mechanism that leads to repair of damaged DNA."

If cells pass this quality control checkpoint, they can resume the process of dividing into two daughter cells. If, however, major irreparable discrepancies occur in the genetic code, cells are shunted toward a molecular sequence that leads to death, or apoptosis. Cells have the genetic knowledge to sacrifice themselves for the greater good of the organism rather than to pass on errant genetic codes that can lead to disease. Genetic errors that sneak past the cell's quality control check-points can make the cell prone to develop into cancer.

The Mayo researchers documented that CDK2 infuses high energy into another cellular protein, FOXO1, switching it on as the initial link in a signal that tells the cell to set itself up for apoptosis. CDK2 adds phosphorylation to a specific serine residue on the chain of amino acids that make up FOXO1. In case of robust errors found in the genetic code, CDK2 signals FOXO1 to explicitly call for the cell to produce a set of proteins leading to apoptosis.

"If the cell has minor alterations in the DNA code that can be repaired, those repairs are made," says first author Haojie Huang, Ph.D. "If the genetic message cannot be repaired, our studies show that CDK2 can initiate the steps necessary for cells to order the production of genes involved with cell death, and the errant cell dies without propagating its damaging genetic message to progeny cells of its own."

"As patients and their physicians seek to control or cure tumors, research is providing new approaches to limiting cancer from growing and spreading," Dr. Tindall said. "With this new understanding of the biology driven by critical dual functions of CDK2, the cancer community can focus on ways to regulate a mechanism that the cell contains to prevent damaged genetic messages from being inherited and spread in proliferating tumor cells."



Publication: Current issue of Science
On the web: www.mayoclinic.org 

Advertise in this space for $10 per month. Contact us today.


Related Pharmacotherapy News
Anthracycline induced heart damage can be reduced by prolonging infusion time
Genomic signatures to guide the use of chemotherapeutics
CDK2/FOXO1 as drug target to Prevent Tumors
Gleevec can be toxic to the heart
AS101 protects the testis from the effects of paclitaxel
Fibrasorb - New device that could cut chemotherapy deaths
Serendipity versus planning - cancer drugs of the future?
Sunitinib Approved for Gastrointestinal Stromal Tumors (GIST) and Kidney Cancer
Celecoxib able to control chemotherapy resistant tumor cells
Inhibiting EAT-2 with medications could boost NK cell activity

Subscribe to Pharmacotherapy Newsletter

Enter your email address:


 Additional information about the news article
Others on the team included Kevin Regan; Zhenkun Lou, Ph.D.; and Junjie Chen, Ph.D. The research was supported by the National Cancer Institute and the T.J. Martell Foundation.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)